Given the implications of these findings, GPR75, GPR56, M3R, and CB1R emerge as promising candidates for novel therapeutic targets in the treatment of diabetes and obesity, especially when combined with liraglutide, and in patients less or unresponsive to liraglutide. Here, GPR75 is linked to obesity due to melanocortin 4 receptor deficiency.